Single-dose radiation therapy equivalent to conventional treatment for most women with early-stage breast cancer

For most women with early-stage breast cancer, a single dose of targeted radiation therapy during surgery is as effective as conventional radiation therapy and requires multiple visits after surgery.

This combination of targeted radiation therapy (limited to the area surrounding the tumor) is given immediately Surgery Called the target Intraoperative radiation therapy.. Traditional radiation therapy involves repeated doses to the entire breast for days after surgery.

Survey results issued by BMJ Today, intraoperative radiation therapy has an approximately 80% chance of avoiding the entire course of conventional radiation therapy, fewer side effects, and survival or cancer Return.

An international team of researchers aims to compare the long-term effects of targeted intraoperative radiation therapy (TARGIT-IORT) with conventional whole breasts External beam radiation therapy (EBRT) Women with early breast cancer.

While the results from previous reports of intraoperative radiation therapy for single doses were promising, doctors waited for long-term results before more widely adopting this procedure.

The new findings are based on 2,298 women over the age of 45 who were subjected to breast-conserving surgery (mastectomy) at 32 centers in 10 countries in the United Kingdom, Europe, Australia, the United States, and Canada.

Between March 2000 and June 2012, 1,140 women were randomized to receive targeted intraoperative radiation therapy (TARGIT-IORT) and 1,158 received external beams Radiation therapy (EBRT).

TARGIT-IORT was given as a single dose immediately after surgery under the same anesthesia as part of the same surgery, and EBRT was given as a standard daily dose for 3-6 weeks after surgery.

Long-term results show that TARGIT-IORT was no worse than EBRT. After five years of monitoring, the risk of local recurrence was 2.11% for TARGIT-IORT, compared to 0.95% for EBRT. This 1.16% difference is not considered clinically significant.

TARGIT-IORT had 13 local recurrences (24 of 1,140 vs. 11 of 1,158) compared to EBRT in the first five years post-surgery, but 14 were fewer (1,140) 42 out of 1,158 out of 1,158).

Local recurrence-free survival (167 vs 147 events), mastectomy-free survival (170 vs 175 events), overall survival (110 vs 131 events) and breast cancer over a longer follow-up period (average 8.6 years, up to 18.9 years) Death (65 to 57 events).

Mortality from other causes was significantly lower in TARGIT-IORT compared to EBRT (45 vs. 74 events). The main risk factors for such deaths (age and body mass index) were in good agreement between groups.

Researchers point out the limitations of some studies, such as over-diagnosis of non-invasive local recurrences that affect outcomes, and do not collect all risk factors behind death from causes other than breast cancer. There is none. However, the strengths include a randomized design, long sample sizes, and high levels of complete follow-up over time, with results that are reliable and robust.

As a result, the researchers found that risk-adapted single-dose TARGIT-IORT during mammary tumor resection was an effective alternative to EBRT and had a comparable long-term tumor suppressive effect in most patients with early-stage breast cancer. There is less breast cancer outside the breast.-Death from cancer.”

Single-dose TARGIT-IORT during lumpectomy should be accessible to the health care professional and discussed with the patient at the time of surgery. milk Cancer is planned,” they conclude.